Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.37 |
| ▸ | RELA | Q04206 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.32 |
| ▸ | DNTT | P04053 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900417 | 0.94 | DNTT (0.36) | CYP19A1ALDH1A1PDCD4DNTTGRM2 | |
| SCHEMBL6897244 | 0.92 | DNTT (0.39) | CYP19A1ALDH1A1PDCD4DNTTGRM2 | |
| SCHEMBL6902526 | 0.92 | DNTT (0.39) | CYP19A1ALDH1A1PDCD4DNTTGRM2 | |
| SCHEMBL6901633 | 0.92 | DNTT (0.39) | CYP19A1ALDH1A1PDCD4DNTTGRM2 | |
| SCHEMBL6903979 | 0.92 | DNTT (0.39) | CYP19A1ALDH1A1PDCD4DNTTGRM2 | |
| SCHEMBL6901472 | 0.88 | — | — | |
| SCHEMBL4864903 | 0.81 | NFKB1 (0.38) | NFKB1NFKB2RELACYP19A1 | |
| SCHEMBL6902657 | 0.79 | — | — | |
| SCHEMBL13170733 | 0.79 | — | — | |
| SCHEMBL17500024 | 0.78 | ACHE (0.34) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833481-B2 | Catalytic dehydrative isomerization | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1316541-A1 | Process for producing 2-alkyl-2-cyclopentenones | Takasago International Corporation (JP) | 2003-06-04 | — | — | EP | disclosed |
| CN-1421429-A | Process for producing 2-alkyl-2-cyclopentenone | TAKASAGO PERFUMERY CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
| US-4540825-A | REARRANGEMENT OF 4-CYCLOPENTENONES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | HSD3B2, DHPS, HSD3B1 | NFKB1 3676/4885NFKB2 2982/4885RELA 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.